Business Wire

Galderma to Unveil Ground-breaking Data From Across Its Leading Dermatology Portfolio and Showcase Major Update for Sensitive Skincare Brand CETAPHIL ® at the 2021 EADV Congress

Share

Galderma’s presence at the 2021 European Academy of Dermatology and Venereology (EADV) virtual congress on September 29 – October 2 will reveal new data and showcase the company’s sophisticated portfolio and services across the spectrum of dermatology. The company’s redesigned virtual booth will have dedicated areas presenting Galderma’s innovations in Consumer Care and Prescription Medicine.

Unveiling new data in Prescription Medicine

The congress will see the unveiling of exciting new data from Galderma relating to rosacea, acne, actinic keratosis, atopic dermatitis and prurigo nodularis. Attendees will have the opportunity to ask questions to the faculties during live Q&A sessions.

On Thursday, September 30, Professor Alison Layton^ will chair the symposium Personalizing Acne: Consensus of Experts to Optimize Acne Management. Together with her co-speakers, Professor Layton will provide practical solutions for longitudinal management of acne.

On the same day, Professor Gil Yosipovitch^ will present the symposium Prurigo Nodularis: From Patient to Pathway, which will discuss the multi-dimensional impact of the disease and reveal new clinical data for the investigational drug, nemolizumab*.

The symposium Moderate to Severe Atopic Dermatitis – A Disease in the Skin and Beyond will take place on Friday, October 1. Chaired by Professor Diamant Thaçi, the session will cover the role of neuro-immune cytokine IL-31 in atopic dermatitis and present emerging clinical data on the effect of nemolizumab* in blocking IL-31 signaling in the disease.

In the symposium New insights on Papulopustular Rosacea and Systemic Therapy on October 1, the speakers will discuss the importance of long-term management strategies in rosacea. Dr. James Q. Del Rosso^ will present original data on the impact of 52 weeks’ use of doxycycline 40mg MR on relapse rate in moderate to severe papulopustular rosacea patients.

On Saturday, October 2, Professor Rolf-Markus Szeimies^ and Professor Serge Mordon^ will host the industry hub Artificial Daylight Photodynamic Therapy: Advancing Actinic Keratosis Treatment. They will present the newly approved modality and main approved artificial daylight devices, as well as a demonstration video.

Galderma will also showcase its latest acne treatment, AKLIEF® (trifarotene) Cream, 0.005%, specifically designed for both facial and truncal acne.

Showcasing advanced solutions in Consumer Care

Visitors will be able to explore highlights from the CETAPHIL® portfolio of 61 products and the largest update in the brand’s 70-year history. As part of the update, CETAPHIL’s iconic, best-selling cleansers and moisturizers—Gentle Skin Cleanser, Daily Facial Cleanser, Moisturizing Cream, Moisturizing Lotion, and Advanced Relief Lotion—have been reformulated. With their dermatologist-backed blend of hydrating and skin-nourishing ingredients, including niacinamide, panthenol and hydrating glycerin, the range of products helps improve the overall resilience of sensitive skin.

CETAPHIL’s latest research will be unveiled through two dedicated symposia. On Thursday, September 30, Dr. Krzysztof Piotrowski^ will chair the symposium Pediatric Atopic Dermatitis: CurrentDevelopments. Professor Adelaide Hebert^ will focus on the latest updates in the field of pediatric atopic dermatitis while Dr. Mark Koh^ will then present his findings and answer the question, “Is it possible to prevent atopic dermatitis from birth?”.

On Friday, October 1, Professor Giovanni Pellacani^ will chair the symposium Advancing Sensitive Skin: Diagnosis, Morphological Traits and Epidemiology. Key speakers Professor Laurent Misery^ and Dr. Emilie Brenaut^ will present their latest research findings and focus on what sensitive skin is, how it can be distinguished from non-sensitive skin and methods for profiling.

Experts from BENZAC® and LOCERYL® will present new findings relating to maskne and onychomycosis through two industry hubs: on Thursday, September 30, Dr. Markus Reinholz^ will chair The Many Faces of Maskne – a New Skin Burden / an Upcoming Disease, featuring speaker Dr. Anne-Charlotte Kuna^. On Friday, October 1, Dr. Dieter Reinel^ will host Onychomycosis Update – Novel Findings: Prevalence, Epidemiology and Topical Therapy.

* Nemolizumab is an investigational drug not approved for any indication in any jurisdiction.

^All speakers are paid consultants of Galderma.

“Galderma is a proud partner of the EADV Congress and we are thrilled to be showcasing our latest innovations and data across our dermatology portfolio. As a company, we are fully committed to advancing dermatology for every skin story.”

BALDO SFORZOLINI, Ph.D.

GLOBAL HEAD OF R&D, GALDERMA

About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information:

About prurigo nodularis
Prurigo nodularis (PN) is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated intense unrelenting itch.10 While PN can occur at any age, it is most likely to affect people between the ages of 40 and 69, frequently leading to severe impairment in quality of life.11
The global prevalence of PN is unknown as there are no studies describing the epidemiology of the condition. In the U.S., the latest estimate is that PN affects 52.9 people in every 100,000. In the European context, rates of between 0.65 and 11.1 per 10,000 population have been reported. In addition to natural variation, this relatively wide range of estimates is partly due to differences in case definition and the representativeness of the study populations.12

About nemolizumab
Nemolizumab is a first-in-class humanized monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.6 IL-31 plays a key role in multiple disease mechanisms in both atopic dermatitis and prurigo nodularis, a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus (itching). With its unique role in directly stimulating sensory neurons related to itch and contributing to inflammation and barrier dysfunction, IL-31 is the bridge between the immune and nervous systems while directly acting on structural cells in the skin. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016 – worldwide except Japan and Taiwan. Nemolizumab is an investigational agent under clinical development for the treatment of atopic dermatitis and prurigo nodularis and its safety and efficacy have not been fully evaluated by any regulatory authority. Nemolizumab was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of pruritus associated with prurigo nodularis.

About AKLIEF
In the European Union, AKLIEF® (trifarotene 50 mcg/g cream) is indicated for the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present. It is the only topical retinoid that specifically targets retinoic acid receptor gamma (RAR-γ), the most common RAR in the skin.13, 14 National marketing authorizations across concerned European member states will follow in 2020.

About CETAPHIL
CETAPHIL was developed by a leading pharmacist more than 70 years ago as a gentle, yet powerful formula to clean without stripping and moisturize without clogging. CETAPHIL is the #1 dermatologist-recommended brand in Germany and the #1 doctor-recommended sensitive skincare brand in the U.S. and is now available in Switzerland. New additions to the brand are regularly developed with the help of leading global skincare experts, providing innovative skincare technologies for sensitive skin that help restore, protect, and maintain skin health every day. For more information, visit www.cetaphil.com.

About BENZAC
BENZAC is an acne brand proposing treatments based on Benzoyl Peroxide active ingredient, as well as acne specific regimen companion products (including cleansers and moisturizers).

About LOCERYL
LOCERYL is the number one nail antifungal brand globally.16 Its treatment is based on amorolfine active ingredient.

-----------------

1. Tan J, et al. Prevalence and severity of facial and truncal acne in a referral cohort. J Drugs Dermatol. 2008;7(6):551–6.

2. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol 2013;168:474–85.

3. Hay RJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2014;134:1527–34.

4. Del Rosso JQ, et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol 2007;6:597–600.

5. Layton AM, et al. Reviewing the global burden of acne: how could we improve care to reduce the burden? Br J Dermatol 2021;184:219–225.

6. Saleem M. et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591-599. DOI: 10.1080/09546634.2017.1290205

7. Langan S. et al. Atopic dermatitis. The Lancet. 2020;396(10247):345-360. DOI: https://doi.org/10.1016/S0140-6736(20)31286-1

8. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab 2015;66(suppl1):8-16. DOI: https://doi.org/10.1159/000370220

9. Atopic Eczema – Symptoms. NHS. Available from: https://www.nhs.uk/conditions/atopic-eczema/symptoms/ Accessed: March 2021.

10. Galderma. Data on File.

11. Atopic Eczema – Symptoms. NHS. Available from: https://www.nhs.uk/conditions/atopic-eczema/symptoms/ Accessed: March 2021

12. Morgan LI. Christopher. Epidemiology of prurigo nodularis in England. 2021.

13. Aubert J, et al. Br J Dermatol 2018;179:442–56.

14. Fisher GJ, et al. J Biol Chem 1994;269(32):20629–35.

15. Health Canada. Approval of Aklief. Available at: Register of Innovative Drugs - Canada.ca (last access December 2019)

16. Nicholas Hall’s global CHC database, DB6

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Lauren Starr
Head of Franchise Communications
media@galderma.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Spotlight on Iceland’s Capital City Shines Even Brighter With the Arrival of The Reykjavik EDITION21.10.2021 17:30:00 CEST | Press release

A flourishing culinary hotspot with cool cafés, a rollicking nightlife and an epic music scene, the spotlight is shining brightly on Iceland’s hip capital city and, with typical finesse, the arrival of The Reykjavik EDITION further cements EDITION Hotels' uncanny ability to land in just the right place at the right time. “Reykjavik is a really cool, young city -perfect for our brand,” says Ian Schrager, the visionary pioneer of the boutique hotel concept, PUBLIC and EDITION creator. “We think this is Reykjavik’s time and we’re right here at the very heart of it and at the perfect time.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005764/en/ The Reykjavik EDITION (Photo: Business Wire) Opening in preview on November 9th, 2021, The Reykjavik EDITION will set a new standard as the city’s first truly luxury hotel experience, combining the best of the Icelandic capital with the personal, intimate and individual experienc

MediaTek Selected to Power Vewd for Automotive Platform21.10.2021 16:41:00 CEST | Press release

Vewd, the leading provider of OTT software solutions, today announced that MediaTek’s Autus I20 (MT2712) chipset was selected as the first reference platform to power Vewd for Automotive, a white-labeled, cloud-managed content aggregation and monetization solution for in-vehicle infotainment equipment providers and car manufacturers. MediaTek’s customer base, streaming ecosystem partnerships, and strong technical capabilities make it the strongest supplier to meet the needs of car manufacturers. Together, Vewd and MediaTek will target Strategy Analytics’ estimated 70 million connected cars on the road by 2025. Vewd for Automotive solves key rear-seat content challenges facing manufacturers through a turnkey solution ready for deployment. For manufacturers, content in the car represents an increasing consumer demand, along with the demand for connectivity that provides additional after-sale branding and revenue opportunities. By partnering with content providers, manufacturers can enabl

Biognosys to Present Major Scientific and Technological Advances at the ASMS 2021 Mass Spectrometry Conference21.10.2021 16:00:00 CEST | Press release

Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry (ASMS) Annual Conference from October 31st to November 4th in Philadelphia (USA). Biognosys will present a record number of 3 oral presentations, 10 scientific posters, 2 poster collaborations, 1 workshop panel, and 2 Spectronaut™ breakfast seminars. In addition, their team of scientific experts will be present at booth #224 to answer questions and demo software. Further demo sessions will be offered at the Bruker Daltonics booth #719. Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly in the areas of plasma proteomics, immunopeptidomics, and proteomics data analysis. Lukas Re

SHV Energy Implements Global Remote LPG Tank Monitoring With Sigfox Netherlands’ 0G Network and Reduces Carbon Emissions21.10.2021 16:00:00 CEST | Press release

SHV Energy and Sigfox are rolling out a global LPG tank level monitoring solution. The implementation has started in France, Belgium and Germany and is already generating lower carbon emissions and improved customer satisfaction. Over the next three years, 50,000 units will be rolled out worldwide. Sigfox’s IoT (Internet of Things) asset monitoring capability enables SHV Energy to reduce the cost of tank level monitoring, while increasing efficiency and productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005065/en/ SHV Energy LPG tank (Photo: Sigfox) SHV Energy, a leading global distributor of off-grid energy such as LPG, LNG, biofuels and renewables, with 30 million customers in 25 countries and 16,700 employees, selected to work with Sigfox, a world’s leading IoT communication service provider and 0G network pioneer. SHV Energy set-up a Telemetry Centre of Excellence and used Sigfox’ solutions and partner At

SSZN Selects Newsight's NSI1000 Chip for Its Advanced Industry 4.0 Production Line Sensors21.10.2021 15:50:00 CEST | Press release

Newsight Imaging Ltd., an innovative semiconductor company developing machine vision sensors, spectral vision chips and systems, announces a commercial agreement with SSZN. SSZN is a leader in developing smart industry 4.0 solutions for supporting automated production line supervision. Newsight will provide SSZN with the NSI1000 - its new and advanced sensor chip. The deal follows a successful design-win where SSZN conducted an evaluation using the NSI1000 chip, closely supported by Newsight's engineering teams in Israel and Shenzhen. The first order of 100,000 chips will be supplied in the upcoming months. The NSI1000 CMOS Image sensor chip, launched by Newsight last year, consists of 32 lines of 1024 pixels and it supports multiple modes, such as multi-triangulation for state-of-the-art accuracy and fast operation on production line inspection. The sensor implements Newsight's enhanced Time of Flight (eTOF™) technology for advanced, long-range, and high-resolution 3D depth image capt

Esper and Lenovo Collaborate on Android Device Deployment in Enterprises21.10.2021 15:05:00 CEST | Press release

DevOps for Devices leader Esper and Lenovo™are teaming up to place Esper software on key models of Lenovo Android tablets and other intelligent business devices. This collaboration allows enterprises that manage large fleets of devices to focus on their critical line-of-business applications, leaving the device infrastructure and management tasks to Lenovo and Esper’s joint solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005372/en/ Lenovo K10 Tablet (Photo: Business Wire) As the fastest-growing tablet maker (YoY) last quarter1, Lenovo’s expertise in smarter device design, engineering and user experiences combines with Esper’s modern, DevOps-powered device infrastructure software that lets organizations of every size and segment (e.g. healthcare, retail, hospitality), easily set up, manage, better secure, and maintain large fleets of devices on their journey to digital transformation. “With proprietary features

Finalist Teams Selected in $10M ANA Avatar XPRIZE Competition21.10.2021 15:00:00 CEST | Press release

XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, announced today that 15 teams from 8 countries are advancing to the finals round of the $10M ANA Avatar XPRIZE competition. Sponsored by All Nippon Airways (ANA), Japan’s largest airline, the Avatar XPRIZE is a four-year global competition focused on the development of an avatar system that will deploy a human’s senses, actions, and presence to a remote location in real time, leading to a more connected world. In the future, avatars could help provide critical care and deploy immediate responses in emergency situations, or offer opportunities for exploration and new ways of collaboration, stretching the boundaries of what is possible and maximizing the impact of skill and knowledge sharing. These avatars must demonstrate the ability to execute tasks across a variety of real-world scenarios and convey a sense of presence for both the operator and the recipient in those inte

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom